Chemistry:E-52862

From HandWiki

E-52862, also known as sigma-1 receptor antagonist (S1A, S1RA), as well as MR-309, is a selective sigma-1 receptor antagonist, with a reported binding affinity of Ki = 17.0 ± 7.0 nM, selective over the sigma-2 receptor and against a panel of other 170 receptors, enzymes, transporters and ion channels.[1][2] In preclinical studies, S1RA has demonstrated efficacy in relieving neuropathic pain and pain in other sensitizing conditions, associated with an improvement of the emotional negative state.[2][3][4][5]

S1RA is being developed by Esteve for the treatment of neuropathic pain and the potentiation of opioid analgesia and has successfully completed Phase I clinical trials showing good safety and tolerability, and a pharmacokinetic profile compatible with once a day oral administration.[6] Phase II clinical trials are currently underway, making S1RA the first selective sigma-1 receptor antagonist evaluated in humans for these conditions.

As of 2025, Phase II trials on human patients have made progress. In European patients with chronic postsurgical pain and painful diabetic neuropathy, the drug showed clinically significant reduction of baseline and worst pain in patients with non-spinal injuries with chronic postsurgical pain. The painful diabetic neuropathy group had a similar reduction in pain, although due to a particularly strong placebo response, more studies will be needed to detangle the true extent of the effects.[7]

See also

References

  1. ↑ "Synthesis and Biological Evaluation of the 1-Arylpyrazole Class of σ1 Receptor Antagonists: Identification of 4-{2-[5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862)". J. Med. Chem. 55 (19): 8211–8224. 2012. doi:10.1021/jm3007323. PMID 22784008. 
  2. ↑ 2.0 2.1 "Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization". Br. J. Pharmacol. 166 (8): 2289–2306. 2012. doi:10.1111/j.1476-5381.2012.01942.x. PMID 22404321. 
  3. ↑ "Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice". J. Pain 13 (11): 1107–1121. 2012. doi:10.1016/j.jpain.2012.08.006. PMID 23063344. 
  4. ↑ "Operant self-administration of a sigma ligand improves nociceptive and emotional manifestations of neuropathic pain". Eur. J. Pain 17 (6): 832–843. 2013. doi:10.1002/j.1532-2149.2012.00251.x. PMID 23172791. 
  5. ↑ "σ1 receptors are involved in the visceral pain induced by intracolonic administration of capsaicin in Mice". Anesthesiology 118 (3): 691–700. 2013. doi:10.1097/ALN.0b013e318280a60a. PMID 23299362. 
  6. ↑ "Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies". Br. J. Clin. Pharmacol. 75 (1): 103–117. 2013. doi:10.1111/j.1365-2125.2012.04333.x. PMID 22607269. 
  7. ↑ Gálvez, Mayoral, Cebrecos, Medel, Morte, Sust, Vaqué, Montes-Pérez, Neira-Reina, Cánovas, Margarit, & Bouhassira (January 2025). "E-52862—A selective sigma-1 receptor antagonist, in peripheral neuropathic pain: Two randomized, double-blind, phase 2 studies in patients with chronic postsurgical pain and painful diabetic neuropathy.". European Journal of Pain 29 (1). doi:10.1002/ejp.4755. https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejp.4755. 





Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:E-52862&oldid=4437320"